AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03096769 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ergonomist
Description: The intervention consists of each surgeon meeting with an ergonomist where the ergonomist will adjust the console settings and chair height to an ergonomically optimal position.
Study NCT01849068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe 10 mg/d for 12 weeks
Study NCT01849068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 weeks
Study NCT01028638 — intervention group
Intervention type: OTHER
Intervention: 89Zr-bevacizumab PET scan
Description: A tracer dose of 89Zr-bevacizumab (37 MBq, 5 mg protein dose) is given intravenously at day -3, day 11 and day 39.~PET scans are made on day 1, day 15 and day 43.
Study NCT00095745 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Antidepressant + Aripiprazole
Description: Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-30mg Aripiprazole, once daily, 52-weeks.
Study NCT02222363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLX600
Description: Patients will receive a dose of VLX600 by 4-hr intravenous infusion using a central venous catheter on Days 1, 8, and 15 of each 28-day treatment cycle. There are the following dose cohorts: 10, 20, 40, 80, 160, and 210 mg VLX600. It is anticipated that patients will receive 6 treatment cycles. In the absence of unacceptable toxicity and disease progression, patients have the option of continuing treatment beyond 6 cycles, if the investigator determines that the patient may benefit further from it.
Study NCT04032873 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: After Initial Treatment Decision
Description: Monetary cost information is relayed after the initial consult with the treating physician, after the treatment decision is made.
Study NCT01411995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel
Description: 3-5cc of 2% lidocaine gel will be applied to the lip of the cervix and within the endocervical canal prior to Intrauterine device insertion
Study NCT00878969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan (ARB)
Study NCT00878969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramipril (ACE inhibitor)
Study NCT00878969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00792246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voriconazole
Description: Voriconazole formulation will be changed from oral to intravenous at the same dose the subject is currently receiving per standard of care.
Study NCT00688935 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 0.1-3 mg, daily, up to 1 year (minimum duration of 6 weeks)
Study NCT01411995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water based lubricant
Description: 3-5cc of water based lubricant will be applied to the lip of the cervix and within the endocervical canal prior to intrauterine device insertion
Study NCT01420783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR302503
Description: Pharmaceutical form:capsule~Route of administration: oral
Study NCT01555320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qishen Yiqi Dripping Pills
Description: One packet of Qishen Yiqi Dripping Pills (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
Study NCT01555320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Qishen Yiqi dripping pills dummy
Description: One packet of Qishen Yiqi Dripping Pills dummy (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
Study NCT00738673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix
Description: Starting dose of 240 mg (40 mg/mL). Maintenance doses of 80 mg (20 mg/mL).
Study NCT01349439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 1mg per Kg (participant weight)
Study NCT01349439 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Short acting + long acting propranolol + memory reactivation
Description: After completing the double-blind phase of the study, participants will receive short acting propranolol 1mg/kg (patient weight) + long acting propranolol (1 or 1.5 mg/kg) followed by memory reactivation. Dose level for the long-acting propranolol will be randomly assigned across participants.
Study NCT01647984 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ritmonutra
Description: Ritmonutra ® contains: 720 mg of Fish Oil with Omega-3, including 480 mg of EPA and 40 mg of DHA, Hawthorn (extract from Crataegus mongyna) 300 mg equivalent to 5.4 mg of vitexin, 4 mg of Astaxanthin and 36 mg of Vitamin E
Study NCT01647984 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02872610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help Online
Description: The internet-based self-help program consist of 6 modules that each take a week to complete. Every module consists of a theoretical section, a compulsory exercise, and several optional exercises: Participants are encouraged to spend a minimum of 30 minutes every day with the self-help program. On the website, the participants in the intervention condition may also access an Acute Help page where information on help options are listed and a My Profile page where changes to login and contact details may be made, also, the informed consent form is found here. Participants may furthermore access a message system where they can write questions to the trial manager.
Study NCT04546321 — intervention group
Intervention type: OTHER
Intervention: serum L carnitine level measuring
Description: The serum level of total L carnitine was measured for both HIE and TTN cases
Study NCT03633149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer tablet-delivered C4H
Description: Two session CHOICES intervention targeting ineffective contraception and risky alcohol use and/or cigarette smoking and/or marijuana use to reduce the risk of a substance-exposed pregnancy delivered on a computer-tablet.
Study NCT03633149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-delivered C4H
Description: Two session CHOICES intervention targeting ineffective contraception and risky alcohol use and/or cigarette smoking and/or marijuana use to reduce the risk of a substance-exposed pregnancy delivered by a counselor.
Study NCT03633149 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Advice
Description: Brief advice delivered by a research associate about healthy behaviors for women including use of contraception and alcohol, tobacco, and marijuana use
Study NCT02767492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioD Restore
Description: Investigational product, BioD Restore, will be injected into the articular space of the knee.
Study NCT02767492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog
Description: Active comparator, Kenalog steroid, will be injected into the articular space of the knee.
Study NCT01305889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: problem solving therapy
Description: 12 weeks of weekly 45 minute sessions of problem solving therapy
Study NCT01305889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: 12 weeks of sertraline; 25 mg for one week, 50 mg for 3 weeks; then 100 mg/day for 4 weeks; then 150 mg/day for 4 weeks based on tolerability and response
Study NCT02280616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose budesonide tablet
Description: 1mg budesonide tablet twice daily AND 5ml placebo suspension twice daily
Study NCT02280616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose budesonide tablet
Description: 2mg budesonide tablet twice daily AND 5ml placebo suspension twice daily
Study NCT02280616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose budesonide suspension
Description: placebo tablet twice daily AND 5ml \[0.4mg budesonide/ml\] suspension twice daily
Study NCT02280616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet twice daily AND 5ml placebo suspension twice daily
Study NCT01765777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Medicine
Study NCT01765777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Study NCT03275675 — intervention group
Intervention type: DRUG
Intervention: Oral anticancer medications
Description: All the oral medications for cancer treatment (hormonal, cytotoxic and targeted therapies)
Study NCT02691936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 fractionated vaginal laser
Description: Intravaginal treatment with fractional microablative CO2 laser at baseline, 6 weeks and 3 months
Study NCT02691936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrogens, Conjugated (USP)
Description: Conjugated estrogen cream 0.5g (equivalent of 0.625 mg of conjugated estrogen) daily for two weeks then twice weekly for 24 weeks
Study NCT02120820 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multisensory environment (MSE)
Description: Participants are staying in multisensory environment (MSE only) for 30 minutes in each session, and twice per week for 10 weeks. An enabler stays with the participant throughout the session.
Study NCT02120820 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Massage therapy (MT)
Description: A trained massage therapist provides 15 minutes massage therapy (MT) to the participants, twice a week for 10 weeks. The massage therapist acts as an enabler.
Study NCT02120820 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Usual residential care will be given to these participants. Only attention and social interactions from the enabler will be provided.
Study NCT02120820 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Massage therapy in multisensory environment (MT-MSE)
Description: Participants receive 15 minutes massage therapy while staying in multisensory environment for 30 minutes, twice a week for 10 weeks.
Study NCT03431662 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ellipse IM HTO Nail
Description: A CT scan will be performed at 3 and 6 months postoperatively to assess the healing of the osteotomy site. Endpoint is 6 months.
Study NCT01378481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT01378481 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo fractionated stereotactic radiation therapy
Study NCT01378481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01378481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03431662 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TomoFix
Description: A CT scan will be performed at 3 and 6 months postoperatively to assess the healing of the osteotomy site. Endpoint is 6 months.
Study NCT02010281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS of prefrontal or motor cortex
Description: description:rTMS of the motor or prefrontal cortex (repetitive magnetic stimulation targeting the motor or prefrontal cortex) assisted with neuronavigation
Study NCT02010281 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: rTMS of prefrontal or motor cortex
Description: description:rTMS of the motor or prefrontal cortex (repetitive magnetic stimulation targeting the motor or prefrontal cortex) assisted with neuronavigation
Study NCT01437917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20% amylose bread
Description: 20% amylose bread
Study NCT01437917 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10% amylose bread
Description: 10% amylose bread
Study NCT01437917 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrates
Description: 50g of carbohydrates ingested with 400 ml of water
Study NCT00279617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levetiracetam
Description: open label levetricetam
Study NCT01378481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo neurosurgery
Study NCT04617665 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: One-handed mask ventilation
Description: Using one-handed mask ventilation techniques during induction of general anesthesia
Study NCT04617665 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Two-handed mask ventilation
Description: Using two-handed mask ventilation techniques during induction of general anesthesia
Study NCT04018261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated T-Lymphocytes
Description: Activated T-Lymphocytes will be infused intravenously in a single-dose
Study NCT03081559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Divas
Description: Peer-based counseling to improve medication adherence and engagement in care
Study NCT04021147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise plus action observation
Description: Orofacial exercise plus action observation (video) of the same exercise
Study NCT04021147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise plus motor imagery
Description: Orofacial exercise plus motor imagery of the same exercise
Study NCT04021147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise plus visual mirror feedback
Description: Exercise plus visual mirror feedback
Study NCT04021147 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Orofacial exercises
Study NCT04365738 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitation
Description: Chest and diaphragm respiration, in-house mobilization, joint range of motion exercises was performed to the patients as breathing exercises.
Study NCT04365738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Chest and diaphragm respiration, in-house mobilization, joint range of motion exercises was performed to the patients as breathing exercises.
Study NCT03761407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg GRT0151Y
Description: 100 mg capsule (1 x 100 mg capsule)
Study NCT03761407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 125 mg GRT0151Y
Description: 125 mg (1 x 100 mg capsule and 1 x 25 mg capsule)
Study NCT03761407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg GRT0151Y
Description: 150 mg (1 x 100 mg capsule and 1 x 50 mg capsule)
Study NCT03761407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225 mg GRT0151Y
Description: Day 1: 150 mg (1 x 100 mg capsule and 1 x 50 mg capsule) Day 2 - 5: 225 mg (2 x 100 mg capsules and 1 x 25 mg capsule)
Study NCT03761407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo capsules using the same dosing regimen as defined in the treatment groups.
Study NCT02722122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIR DNase™
Study NCT00033462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT03692975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical assessment
Description: Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.
Study NCT03692975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation
Description: cognitive tests exploring episodic memories, information processing speed, attention/concentration and working memory.
Study NCT00951509 — intervention group
Intervention type: OTHER
Intervention: Power Mobility Road Test (PMRT)
Description: All subjects will underwent the Power Mobility Road Test (PMRT), and the clinicians scored the driving performance within each condition.
Study NCT03692975 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological evaluation
Description: cognitive tests exploring episodic memories, information processing speed, attention/concentration and working memory.
Study NCT03692975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological evaluation
Description: included questionnaires for depression, anxiety, fatigue, cognitive complaint and reserve
Study NCT03692975 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychological evaluation
Description: included questionnaires for depression, anxiety, fatigue, cognitive complaint and reserve
Study NCT03692975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Evaluation
Description: Diffusion including NODDI, 3DT1 with and without gadolinium, 3D-FLAIR before and after gadolinium infusion, 3D White Matter nulled-MPRAGE, 3D Double-Inversion recovery sequences-weighted imaging and Resting state functional MRI
Study NCT03692975 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI Evaluation
Description: Diffusion including NODDI, 3DT1 with and without gadolinium, 3D-FLAIR before and after gadolinium infusion, 3D White Matter nulled-MPRAGE, 3D Double-Inversion recovery sequences-weighted imaging and Resting state functional MRI
Study NCT03911986 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: R Test 4 External Loop Recorder
Description: The R-Test 4 is an externally worn, re-usable, battery-powered, lightweight ECG monitor, which records events triggered by cardiac arrhythmias. It is worn for 7 days. Cardiac monitoring is triggered by tachycardia or detection of irregular pulses or patient may trigger recording, if the participant experience symptoms (e.g. palpitations). The patient wears 2 chest leads (on one, the R-Test device is attached, weight 42g). The R-Test 4 is CE marked, and uses an FDA-approved algorithm for automatic detection of atrial fibrillation, and permits 5 minutes of pre-event recording and 5 minutes of post-event recording.
Study NCT00742872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosapride Citrate
Description: One 5 mg tablet taken orally three times per day (15 min before meals) for 8 weeks.
Study NCT00742872 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet (identical in shape and form to the actual drug) taken orally three times per day (15 min before meals) for 8 weeks.
Study NCT01783600 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NanoCross .014 balloon catheter
Study NCT04229602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine Hydrochloride Sustained-Release Capsules 75 mg
Description: A generic product manufactured by Beijing Winsunny Pharmaceutical Co., Ltd.
Study NCT04229602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFEXOR® XR
Description: EFEXOR® XR (75mg) produced by Pfizer Ireland Pharmaceuticals(held by Pfizer Healthcare Ireland, distributed by Wyeth pharmaceutical co. LTD)
Study NCT03166540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cup of espresso coffee
Description: Subjects will consume the assigned treatment for one month. Espresso coffee will be prepared by using coffee capsules. Serving size: approximately 45 mL. The last day of the intervention is the sampling day.
Study NCT03166540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cocoa-based products containing coffee
Description: Subjects will consume the assigned treatment (2 products per serving) for one month. Serving size: approximately 37 g. The last day of the intervention is the sampling day.
Study NCT04884113 — intervention group
Intervention type: DEVICE
Intervention: Motorized Spiral enteroscopy
Description: Small-bowel enteroscopy for diagnosis and intervention
Study NCT03177434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycols (PEG) 3350
Description: Evaluating the efficacy of Dicopeg Junior in comparison with lactulose for the treatment of functional constipation in children aged 6 months to 6 years.
Study NCT03177434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose Oral Product
Description: Evaluating the efficacy of Dicopeg Junior in comparison with lactulose for the treatment of functional constipation in children aged 6 months to 6 years.
Study NCT01312233 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Care
Description: Participants allocated to all three treatment groups receive medical care over a 12-week period. Medical treatments are standard therapies for back pain. Medical and osteopathic physicians follow clinical practice guideline recommendations for back pain: focused history and physical exam; limited diagnostic imaging; self-management education; maintaining physical activity as tolerated and local heat/cold application; pharmacotherapy with analgesics and anti-inflammatory agents. Participants not responding to treatment may receive additional therapies such as physical therapy or specialist referral.